The safety profile of semaglutide has been extensively studied outside of AD and is well characterized in T2D and obesity [15, 57,58,59]
Clinical data suggests tirzepatide users lose approximately 1-2 additional pounds per month compared to semaglutide on average, though individual results vary by genetics, diet, and exercise
Clinical studies have validated safety and efficacy in reducing melasma and post-inflammatory hyperpigmentation with minimal adverse effects through enhanced transdermal delivery
If approved, CagriSema would become the first GLP-1 and amylin combination product to reach the market for obesity, a genuinely novel mechanism designation that Novo Nordisk regards as a meaningful point of differentiation regardless of the tirzepatide comparison
EasyDraw at home
You may notice reduced appetite in the first few weeks, while weight loss results may take 4-12 weeks to become noticeable